ImmuCell Gross Profit Over Time
| ICCC Stock | USD 3.72 0.02 0.54% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ImmuCell Performance and ImmuCell Correlation. ImmuCell |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share 2.991 | Quarterly Revenue Growth 0.549 | Return On Assets (0.05) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Gross Profit Analysis
Compare ImmuCell and related stocks such as Transgene SA, Alpha Cognition, and Fennec Pharmaceuticals Gross Profit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FENC | 0.68 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 170 K | 170 K | 0.0 | 1.4 M | 20 M | 21 M |
| LIPO | 11.9 K | 11.9 K | 11.9 K | 11.9 K | 11.9 K | 11.9 K | 11.9 K | 11.9 K | 11.9 K | 11.9 K | (14.3 K) | (1.2 M) | (2.4 M) | (2.6 M) | (2.5 M) |
| HCWB | (421.8 K) | (421.8 K) | (421.8 K) | (421.8 K) | (421.8 K) | (421.8 K) | (421.8 K) | (421.8 K) | (421.8 K) | (421.8 K) | 4.1 M | (543.6 K) | 2.6 M | 560.4 K | 532.3 K |
| MNOV | 52.7 K | 0.0 | 802.6 K | 6 M | 0.0 | (26.7 K) | (14.1 K) | (28.1 K) | (25.9 K) | (23.9 K) | (21.3 K) | 4 M | (212.4 K) | 1000 K | 950 K |
| LCTX | (300 K) | 4.4 M | 1.3 M | 2.1 M | 1.1 M | 1.4 M | 1.9 M | 1.6 M | 1.1 M | 1.1 M | 388 K | 2.5 M | 14 M | 8.3 M | 8.7 M |
| CVKD | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (2 K) | (2.1 K) |
| RZLT | (4.8 K) | (4.8 K) | (4.6 M) | (2.4 M) | (5.8 M) | (8.3 M) | (12.6 M) | 0.0 | (48 K) | (18 K) | (303 K) | (256 K) | (382 K) | (36 K) | (37.8 K) |
| PTIX | 0.0 | 0.0 | 85 K | 0.0 | 0.0 | 0.0 | (534) | (148) | (347) | (339) | (286) | (30.0) | (30.0) | (28.2 K) | (26.8 K) |
| TPST | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | (2 M) | (4.7 M) | (495 K) | (1.1 M) | (1.1 M) | (815 K) | (1.3 M) | (1.8 M) | (381 K) | (400.1 K) |
ImmuCell and related stocks such as Transgene SA, Alpha Cognition, and Fennec Pharmaceuticals Gross Profit description
Gross profit is a required income statement account that reflects total revenue of ImmuCell minus its cost of goods sold. It is profit before ImmuCell operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.My Equities
My Current Equities and Potential Positions
| ImmuCell | ICCC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Maine; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.72
Check out ImmuCell Performance and ImmuCell Correlation. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
ImmuCell technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.